Laboratory monitoring should be done prior to beginning treatment and quarterly until maintenance dose is established
The studys author Dr Nils Krger, of Brigham and Womens hospital and a founding member of the Mass General Brigham healthcare system, said: Despite the widespread morbidity and mortality burden of HFpEF, current treatment options are limited
Less commonly performed but effective is injections to the jaw area
Basic Information Brief Introduction Semaglutide, developed by Novo Nordisk and sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management
In a widely cited New England Journal of Medicine trial using once-weekly semaglutide 2.4 mg plus lifestyle intervention in adults with overweight or obesity without diabetes, participants had a substantial and sustained reduction in body weight over 68 weeks